OncoMatch/Clinical Trials/NCT07737171
Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions
Is NCT07737171 recruiting? Yes, currently enrolling (Sep 2026). Studying Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) for pancreatic cancer.
Treatment: Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) — This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Prior therapy
Must have received: endoscopic ultrasound-guided radiofrequency ablation — treatment of pancreatic lesions
Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Texas Health Science Center at Houston · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07737171 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received endoscopic ultrasound-guided radiofrequency ablation.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages